Glenmark Pharma shares: The company's unit Glenmark Specialty S.A. signed an exclusive licensing deal with China’s Hengrui Pharma for Trastuzumab Rezetecan, a next-gen HER2-targeting ADC. The pact includes an upfront payment of $18 million, milestone payouts of up to $1.093 billion, and royalties on sales.
Finance
September 25, 2025
Glenmark Pharma shares in focus on $1.1 billion deal for oncology drug
Unknown Author
Advertisement
Related Articles
If Notre Dame Wants Another College Football Playoff …
Notre Dame's mission? The Fighting Irish must do more than just win these final seven …
5 hours, 31 minutes ago
229% inflation: How ‘Binance dollars’ became Venezuela’s real …
Venezuela turns to USDT as hyperinflation bites, with merchants pegging prices to Binance P2P dollar …
5 hours, 32 minutes ago
Prediction: Tesla Stock May Be "Dreadful" in 2026
Tesla (NASDAQ: TSLA) investors should prepare for a rocky 2026. At least that's what certain …
5 hours, 42 minutes ago
1 Warren Buffett Stock That Could Go Parabolic …
You may be surprised to learn that the largest investor in Sirius XM Holdings (NASDAQ: …
5 hours, 45 minutes ago